NCT06623162View on ClinicalTrials.gov

Sasanlimab As Maintenance Treatment Based on Clinical Response to Neoadjuvant Treatment in Molecularly Categorized Muscle Invasive Bladder Cancer Patients

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

December 31, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2027

Conditions
MibcMuscle Invasive Bladder Cancer
Interventions
DRUG

gemcitabine + cisplatine

4 cycles

Trial Locations (1)

28050

Hm Sanchinarro, Madrid

Sponsors
All Listed Sponsors
collaborator

MFAR Clinical Research S.L.

UNKNOWN

collaborator

Hospital Universitario 12 de Octubre

OTHER

lead

Fundación de investigación HM

OTHER

NCT06623162 - Sasanlimab As Maintenance Treatment Based on Clinical Response to Neoadjuvant Treatment in Molecularly Categorized Muscle Invasive Bladder Cancer Patients | Biotech Hunter | Biotech Hunter